Details

Autor(en) / Beteiligte

• Neuzil, Petr
• Merkely, Béla
• Erglis, Andrejs
• Marinskis, Germanas
• Groot, Joris R.
• Schmidinger, Herwig
• Rodriguez Venegas, Manuel
• Voskuil, Michiel
• Sturmberger, Thomas
• Petru, Jan
• Jongejan, Niels
• Aichinger, Josef
• Kamzola, Ginta
• Aidietis, Audrius
• Gellér, Laszlo
• Mraz, Tomas
• Osztheimer, Istvan
• Mika, Yuval
• Evans, Steven
• Burkhoff, Daniel
• Kuck, Karl‐Heinz
• Simon, Jaroslav
• Dujka, Libor
• Machalek, Libor
• Király, Ákos
• Molnár, Levente
• Kovács, Attila
• Szabó, Marianna
• Kupics, Kaspars
• Ansaberga, Ieva
• Ansabergs, Janis
• Nesterovics, Nikolajs
• Barysiene, Jurate
• Cruijsen, Marc
• Schellevis, Mindel M.
• Pezawas, Thomas
• Flores, Emilio
• Fullerton, Demian
• Beeftink, Martine M.A.
• Meine, Matthias
• Ascheim, Deborah D.
• Dizon, Jose
• Hanon, Samuel
• Hastings, Harold

Titel

Pacemaker‐Mediated Programmable Hypertension Control Therapy

Ist Teil von

• Journal of the American Heart Association, 2017-12, Vol.6 (12), p.n/a

Ort / Verlag

England: John Wiley and Sons Inc

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Many patients requiring a pacemaker have persistent hypertension with systolic blood pressures above recommended levels. We evaluated a pacemaker‐based Programmable Hypertension Control (PHC) therapy that uses a sequence of variably timed shorter and longer atrioventricular intervals. Methods and Results Patients indicated for dual‐chamber pacing with office systolic blood pressure (oSBP) >150 mm Hg despite stable medical therapy were implanted with a Moderato™ pulse generator that delivers PHC therapy. Patients were followed for 1 month (Run‐In period) with conventional pacing; those with persistent oSBP >140 mm Hg were included in the study and had PHC therapy activated. The co‐primary efficacy end points were changes in 24‐hour ambulatory systolic blood pressure and oSBP between baseline and 3 months. Safety was assessed by tracking adverse events. Thirty‐five patients met the initial inclusion criteria and underwent Moderato implantation. At 1 month, oSBP was <140 mm Hg in 7 patients who were excluded. PHC was activated in the remaining 27 patients with baseline office blood pressure 166±11/80±10 mm Hg despite an average of 3.2 antihypertensive medications. During the Run‐In period, oSBP and 24‐hour ambulatory systolic blood pressure decreased by 8±13 and 5±12 mm Hg (P<0.002), respectively. Compared with pre‐PHC activation measurements, oSBP decreased by another 16±15 mm Hg and 24‐hour ambulatory systolic blood pressure decreased by an additional 10±13 mm Hg (both P<0.01) at 3 months. No device‐related serious adverse effects were noted. Conclusions In pacemaker patients with persistent hypertension despite medical therapy, oSBP and 24‐hour ambulatory systolic blood pressure are decreased by PHC therapy. Initial indications are that this therapy is a safe and promising therapy for such patients. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02282033.